

DESCRIPTION

Source Mouse myeloma cell line, NS0-derived
Glu17-Ser634, with a C-terminal 6-His tag
Accession # P48441

N-terminal Sequence Analysis Glu17

Predicted Molecular Mass 70 kDa

SPECIFICATIONS

SDS-PAGE 83-95 kDa, reducing conditions

Activity Measured by its ability to cleave a fluorogenic substrate, 4-Methylumbelliferyl α -L-iduronide.
The specific activity is >7,500 pmol/min/ μ g, as measured under the described conditions.

Endotoxin Level <1.0 EU per 1 μ g of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Supplied as a 0.2 μ m filtered solution in Sodium Acetate, NaCl and Glycerol. See Certificate of Analysis for details.

Activity Assay Protocol

- Materials**
- Assay Buffer: 50 mM NaOAc, 150 mM NaCl, 0.02% Brij-35 (w/v), pH 3.5
 - Developing Buffer: 0.1 M Tris, pH 9.0
 - Recombinant Mouse α -L-Iduronidase/IDUA (rmIDUA) (Catalog # 9348-GH)
 - Substrate: 4-methylumbelliferyl- α -L-iduronide (Glycosynth, Catalog # 44076), 20 mM stock in DMSO
 - F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
 - Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent

- Assay**
1. Dilute rmIDUA to 0.2 μ g/mL in Assay Buffer. Minimize the number of dilution steps to obtain the best activity results.
 2. Dilute Substrate to 200 μ M in Assay Buffer.
 3. Combine equal volumes of 0.2 μ g/mL rmIDUA and 200 μ M Substrate. Include a Substrate Blank containing Assay Buffer and Substrate.
 4. Incubate for 10 minutes at room temperature.
 5. Dilute mixtures to 0.005 μ g/mL rmIDUA in Developing Buffer.
 6. In a plate load 100 μ L of diluted mixtures.
 7. Read at excitation and emission wavelengths of 365 nm and 445 nm (top read), respectively in endpoint mode.
 8. Calculate specific activity:

$$\text{Specific Activity (pmol/min/}\mu\text{g)} = \frac{\text{Adjusted Fluorescence* (RFU)} \times \text{Conversion Factor** (pmol/RFU)}}{\text{Incubation time (min)} \times \text{amount of enzyme (}\mu\text{g)}}$$

*Adjusted for Substrate Blank.

**Derived using calibration standard 4-methylumbelliferone (Sigma, Catalog # M1381).

- Final Assay Conditions**
- Per Well:
- rmIDUA: 0.0005 μ g
 - Substrate: 5 μ M

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

- Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 6 months from date of receipt, -20 to -70 °C as supplied.
 - 3 months, -20 to -70 °C under sterile conditions after opening.

BACKGROUND

α -L-Iduronidase encoded by the IDUA gene is an important enzyme required for the lysosomal degradation of glycosaminoglycans (GAGS). It hydrolyzes the non-reducing terminal α -L-iduronic acid residues in GAGS including dermatan sulfate and heparan sulfate. Mature mouse IDUA shares 80% aa identity with human IDUA. Mutations in IDUA that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I) (1). MPS I can be classified as three clinical subtypes; Hurler syndrome, Hurler-Scheie syndrome, and Scheie syndrome with decreasing severity, respectively. MPS I causes progressive cellular, tissue and organ damage, and several clinical studies using enzyme replacement therapy show positive results (2, 3). Recently, the IDUA gene has been linked to osteoporosis (4, 5).

References:

1. Scott, H.S. *et al.* (1995) Hum. Mutat. **6**:288.
2. Wraith, J.E. (2005) Expert Opin. Pharmacother. **6**:489.
3. Jameson, E. (2016) Cochrane Database Syst. Rev. **4**: CD009354.
4. Kodric, K. *et al.* (2016) Wien Klin Wochenschr. **128**:480.
5. Niu, T. *et al.* (2016) J. Bone Miner. Res. **31**:358.